Fluorescent molecular peroxidation products a prognostic biomarker of early neurologic deterioration after thrombolysis

Stroke

Volumn 45, Issue 2, 2014, Pages 432-437

  Llombart, Víctor ^a   Dominguez, Carmen ^b   Bustamante, Alejandro ^a   Rodriguez Sureda, Victor ^b   Martín Gallán, Pilar ^b   Vilches, Angel ^b   García Berrocoso, Teresa ^a   Penalba, Anna ^a   Hernández Guillamon, Mar ^a   Rubiera, Marta ^b   Ribó, Marc ^b   Eschenfelder, Christoph ^c,d   Giralt, Dolors ^a   Molina, Carlos A ^b   Alvarez Sabín, José ^b   Rosell, Anna ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Biomarkers; Stroke

Indexed keywords

ALTEPLASE; BIOLOGICAL MARKER; FLUORESCENT MOLECULAR PEROXIDATION PRODUCT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; BRAIN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STROKE PATIENT; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VERY ELDERLY;

BIOMARKERS; STROKE;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CEREBRAL HEMORRHAGE; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; FIBRINOLYTIC AGENTS; FLUORESCENCE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS; PEROXIDES; PROGNOSIS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893742951     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.003431     Document Type: Article

References (31)

1. Taussky P, Tawk RG, Daugherty WP, Hanel RA. Medical therapy for ischemic stroke: review of intravenous and intra-arterial treatment options. World Neurosurg. 2011;76(6 suppl):S9-15.
2. Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):333-343.
3. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2:38-43.
4. Medcalf RL, Davis SM. Plasminogen activation and thrombolysis for ischemic stroke. Int J Stroke. 2012;7:419-425.
5. Domínguez C, Delgado P, Vilches A, Martín-Gallán P, Ribó M, Santamarina E, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke. 2010;41:653-660.
6. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med. 2005;39:51-70.
7. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24:351-371.
8. Usatyuk PV, Natarajan V. Regulation of reactive oxygen species-induced endothelial cell-cell and cell-matrix contacts by focal adhesion kinase and adherens junction proteins. Am J Physiol Lung Cell Mol Physiol. 2005;289:L999-L1010.
9. Chang CC, Wang YH, Chern CM, Liou KT, Hou YC, Peng YT, et al. Prodigiosin inhibits gp91(phox) and iNOS expression to protect mice against the oxidative/nitrosative brain injury induced by hypoxia-ischemia. Toxicol Appl Pharmacol. 2011;257:137-147.
10. Ji H, Zhang X, Du Y, Liu H, Li S, Li L. Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 2012;87:50-59.
11. Shimasaki H. Assay of fluorescent lipid peroxidation products. Methods Enzymol. 1994;233:338-346.
12. Porta EA. Pigments in aging: an overview. Ann N Y Acad Sci. 2002;959:57-65.
13. Marjani A. Lipid peroxidation alterations in type 2 diabetic patients. Pak J Biol Sci. 2010;13:723-730.
14. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol. 2007;14:529-533.
15. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
16. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
17. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
18. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7:1355-1364.
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72, discussion 207.
20. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke. 2012;43:86-91.
21. Dillard CJ, Tappel AL. Fluorescent damage products of lipid peroxidation. Methods Enzymol. 1984;105:337-341.
22. Montezano AC, Touyz RM. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med. 2012;44(suppl 1):S2-S16.
23. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, et al. Association between tPA therapy and raised early matrix metalloproteinase- 9 in acute stroke. Neurology. 2006;66:1550-1555.
24. Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32.
25. Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos M, et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke. 2010;41:1528-1535.
26. Mendioroz M, Fernández-Cadenas I, Alvarez-Sabín J, Rosell A, Quiroga D, Cuadrado E, et al. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients. Cerebrovasc Dis. 2009;28:143-150.
27. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40:e380-e389.
28. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
29. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325-2329.
30. Lin LC, Lee TH, Chang CH, Chang YJ, Liou CW, Chang KC, et al. Predictors of clinical deterioration during hospitalization following acute ischemic stroke. Eur Neurol. 2012;67:186-192.
31. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008;79:1093-1099.